Acquisition will expand DI’s coverage in TexasISG Technologies and optics firm Carl Zeiss have formalized their joint-venture agreement to form Surgical Navigation Specialists (SNS), an image-guided surgery company (SCAN 7/22/98). ISG
Acquisition will expand DIs coverage in Texas
ISG Technologies and optics firm Carl Zeiss have formalized their joint-venture agreement to form Surgical Navigation Specialists (SNS), an image-guided surgery company (SCAN 7/22/98). ISG holds an 80% share in the company, which was formed to produce and market ISGs Windows NT-based image-guided surgery software for the Surgical Navigation Network, a group of medical equipment firms that sell the software.
ISG, of Mississauga, Ontario, will contribute its image-guided surgery technology and assets, as well as its existing sales, marketing, and engineering staff. Thornwood, NY-based Zeiss will contribute technology, working capital, and marketing resources, according to the two firms
In other ISG news, the company moved into the black in its 1998 fiscal year. For the period (end-June), the company had net income of $327,000 (U.S.) compared with a net loss of $2.1 million last year. The company also saw its revenues climb 17% to a record high of $23.7 million during the campaign. Revenues in fiscal year 1997 were $20.2 million.
The company also had a strong fourth quarter. For the period, revenue was $6.6 million, up 12.1% compared with the $5.9 million in sales reported in the same period last year. Net income was $131,000 compared with a profit of $66,000 in 1997.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.